Differential Disposition of Chenodeoxycholic Acid versus Taurocholic Acid in Response to Acute Troglitazone Exposure in Rat Hepatocytes

Tracy L. Marion,* Cassandra H. Perry,† Robert L. St. Claire, III,† Wei Yue,‡ and Kim L. R. Brouwer*†‡

*Curriculum in Toxicology, UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7270; †Qualyst, Inc., Durham, North Carolina 27713; and ‡Division of Pharmacochemistry and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7569

Inhibition of bile acid (BA) transport may contribute to the hepatotoxicity of troglitazone (TRO), a peroxisome proliferator–activated receptor gamma agonist. Typically, studies use taurocholic acid (TCA) as a model substrate to investigate effects of xenobiotics on BA disposition. However, TRO may differentially affect the transport of individual BAs, potentially causing hepatocyte accumulation of more cytotoxic BAs. The effects of TRO on the disposition of [14C]-labeled chenodeoxycholic acid ([14C]CDCA), an unconjugated cytotoxic BA, were determined in suspended hepatocytes and sandwich-cultured hepatocytes (SCH) from rats. (E)-3-[3-[2-(7-chloro-2-quinolinyl)ethenyl]-phenyl][3-(dimethylamino)-3-oxopropyl]thio[methyl]thio]propanoic acid (MK571), a multidrug resistance–associated protein (MRP) inhibitor, was included to evaluate involvement of MRPs in CDCA disposition. Accumulation in cells + bile of total [14C]CDCA species in SCH was sixfold greater than [3H]TCA and unaffected by 1 and 10μM TRO; 100μM TRO and 50μM MK571 ablated biliary excretion and significantly increased intracellular accumulation of total [14C]CDCA species. Results were similar in Mrp2-deficient TR−rat hepatocytes. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis revealed that taurine- and glycine-conjugated CDCA, in addition to unconjugated CDCA, accumulated in hepatocytes during the 10-min incubation. In suspended rat hepatocytes, initial [14C]CDCA uptake was primarily Na+-independent, whereas initial [3H]TCA uptake was primarily Na+-dependent; TRO and MK571 decreased [14C]CDCA uptake to a lesser extent than [3H]TCA. Unexpectedly, MK571 inhibited Na+-taurocholate cotransporting polypeptide and bile salt export pump. Differential effects on uptake and efflux of individual BAs may contribute to TRO hepatotoxicity. Although TCA is the prototypic BA used to investigate the effects of xenobiotics on BA transport, it may not be reflective of other BAs.

Key Words: troglitazone; bile acids; hepatotoxicity; transport; sandwich-cultured hepatocytes.

Troglitazone (TRO) is a peroxisome proliferator–activated receptor gamma agonist used clinically to treat noninsulin-dependent type II diabetes until it was removed from the market following a number of cases of severe idiosyncratic hepatotoxicity. Much research has focused on determining the mechanisms of TRO-mediated hepatotoxicity. One hypothesis is that TRO inhibits hepatic bile acid (BA) transport; inhibition of the bile salt export pump (BSEP) may cause intracellular accumulation of BAs (reviewed in Masubuchi, 2006) and subsequent toxicity due to detergent effects (Delzenne et al., 1992; Pauli-Magnus et al., 2005). Impaired BSEP function is a significant medical issue (reviewed in Pauli-Magnus et al., 2010); however, drug-mediated inhibition of hepatic BA transport as a mechanism of drug-induced liver injury is poorly understood.

Normally, BA disposition is tightly controlled, and hepatic BA concentrations are governed by the rate of synthesis and by basolateral (sinusoidal) and apical (canalicular) transport proteins. On the basolateral membrane, the Na+-taurocholate cotransporting polypeptide (NTCP) mediates Na+-dependent uptake of BAs, whereas organic anion transporting polypeptide (OATP) isoforms mediate Na+-independent uptake of BAs, organic anions, some organic cations, and neutral species (Trauner and Boyer, 2003). On the apical membrane, BSEP is the major canalicular transport protein that mediates biliary excretion of monomeric BAs, whereas multidrug resistance–associated protein (MRP) 2 (MRP2/Mrp2) transports divalent BAs from blood to bile. The basolateral efflux transporters, MRP3, MRP4, and the organic solute transporter, OSTcβ, also may be involved in the excretion of BAs from hepatocytes back into the blood under cholestatic conditions (reviewed in Borst et al., 2007; Soroka et al., 2010).

Taurocholic acid (TCA) is the taurine conjugate of the primary BA cholic acid (CA) that is present in both rats and humans. TCA is utilized commonly as a prototypic BA to study the effect of xenobiotics and drugs, including TRO, on BA transport both in vivo and in vitro. TRO caused the accumulation of [14C]TCA in rat liver tissue (Funk et al., 2001b).
and inhibited Bsep-mediated TCA transport in rat canalicular membrane vesicles (Funk et al., 2001a) and in membrane vesicles from S9 cells overexpressing Bsep from different species (Kis et al., 2009). TRO inhibited TCA uptake and biliary excretion in primary rat sandwich-cultured hepatocytes (SCH) (Kemp et al., 2005) and inhibited TCA transport in both basolateral and canaliculat rat liver membrane vesicles (Snow and Moseley, 2006). Studies by our group in human SCH showed that TRO decreased TCA biliary excretion in a concentration-dependent manner, consistent with BSEP inhibition; Na\(^{+}\)-dependent initial uptake of TCA also was inhibited in rat and human suspended hepatocytes (Marion et al., 2007). TRO also caused intracellular retention of preloaded \([^{3}H]TCA\) in human hepatocytes (Jemnitz et al., 2010).

BAs perform important physiological roles but are cytotoxic and may cause mitochondrial dysfunction and trigger apoptosis or necrosis if they accumulate to high intracellular concentrations. The hydrophobicity of individual BAs is inversely correlated with their affinities for some BA transporters (Byrne et al., 2003). In the liver, the uptake and biliary excretion of BAs is dependent on their concentration, with the highest clearance of TCA. TRO competitively inhibits TCA transport, leading to increased intracellular retention and decreased biliary excretion of TCA. The present study was designed to determine whether TRO differentially affects the hepatic disposition of CDCA versus TCA in rat SCH and suspended hepatocytes. Experiments were designed to determine whether TRO differentially affects the hepatic disposition of individual BAs resulting in greater intracellular accumulation of CDCA compared with TCA, and to examine the mechanism(s) of potential alterations. (E)-3-[[3-[[3-[[3-(7-chloro-2-quinoilinyl)ethenyl]phenyl][3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-propanoic acid (MK571), an MRP inhibitor, was included to investigate the potential involvement of MRPs in CDCA and TCA hepatic disposition.

**MATERIALS AND METHODS**

**Chemicals.** \(^{14}C\)CDCA (50 mCi/mmoll; purity >97%) and \(^{3}H\)CDCA (2.8 mCi/g; purity >97%) were purchased from American Radiolabeled Chemicals, Inc. (St Louis, MO), and \(^{3}H\)TCA (5 Ci/mmol; purity >97%) was purchased from Perkin Elmer (Waltham, MA). TRO was purchased from Biomol (Plymouth Meeting, PA). MK571 sodium salt was obtained from Cayman Chemical (Ann Arbor, MI). Dexamethasone, Hanks’ balanced salt solution (HBSS) premix, and HBSS modified (without calcium chloride, magnesium sulfate, phenol red, and sodium bicarbonate) premix were purchased from Sigma-Aldrich (St Louis, MO). Collagenase (type I, class I) was obtained from Worthington Biochemical (Freehold, NJ), and dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific (Fair lawn, NJ). Gibco brand fetuin bovine serum, recombinant human insulin, and Dulbecco’s modified Eagle’s medium (DMEM) were purchased from Invitrogen (Carlsbad, CA). ITS (insulin, transferrin, and selenium) Universal Culture Supplement Premix and Matrigel Basement Membrane Matrix were obtained from BD Biosciences (Palo Alto, CA). All other chemicals and reagents were of analytical grade and were readily available from commercial sources.

**Hepatocyte isolation and culture.** Hepatocytes were isolated from wild-type or necrosis if they accumulate to high intracellular concentrations. The hydrophobicity of individual BAs is inversely correlated with their affinities for some BA transporters (Byrne et al., 2003). In the liver, the uptake and biliary excretion of BAs is dependent on their concentration, with the highest clearance of TCA. TRO competitively inhibits TCA transport, leading to increased intracellular retention and decreased biliary excretion of TCA. The present study was designed to determine whether TRO differentially affects the hepatic disposition of CDCA versus TCA in rat SCH and suspended hepatocytes. Experiments were designed to determine whether TRO differentially affects the hepatic disposition of individual BAs resulting in greater intracellular accumulation of CDCA compared with TCA, and to examine the mechanism(s) of potential alterations. (E)-3-[[3-[[3-[[3-(7-chloro-2-quinoilinyl)ethenyl]phenyl][3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-propanoic acid (MK571), an MRP inhibitor, was included to investigate the potential involvement of MRPs in CDCA and TCA hepatic disposition.

**MATERIALS AND METHODS**

**Chemicals.** \(^{14}C\)CDCA (50 mCi/mmoll; purity >97%) and \(^{3}H\)CDCA (2.8 mCi/g; purity >97%) were purchased from American Radiolabeled Chemicals, Inc. (St Louis, MO), and \(^{3}H\)TCA (5 Ci/mmol; purity >97%) was purchased from Perkin Elmer (Waltham, MA). TRO was purchased from Biomol (Plymouth Meeting, PA). MK571 sodium salt was obtained from Cayman Chemical (Ann Arbor, MI). Dexamethasone, Hanks’ balanced salt solution (HBSS) premix, and HBSS modified (without calcium chloride, magnesium sulfate, phenol red, and sodium bicarbonate) premix were purchased from Sigma-Aldrich (St Louis, MO). Collagenase (type I, class I) was obtained from Worthington Biochemical (Freehold, NJ), and dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific (Fair lawn, NJ). Gibco brand fetuin bovine serum, recombinant human insulin, and Dulbecco’s modified Eagle’s medium (DMEM) were purchased from Invitrogen (Carlsbad, CA). ITS (insulin, transferrin, and selenium) Universal Culture Supplement Premix and Matrigel Basement Membrane Matrix were obtained from BD Biosciences (Palo Alto, CA). All other chemicals and reagents were of analytical grade and were readily available from commercial sources.
Temperature-dependent accumulation of [14C]CDCA and [3H]TCA in WT rat SCH. Accumulation in WT rat SCH of [14C]CDCA and [3H]TCA in the presence of vehicle was measured at 37°C using the above method. Accumulation at 4°C was carried out using the same method, except that all reagents were kept at 4°C, and all incubations were performed on ice.

Measurement of taurine- and glycine-conjugated CDCA species in WT rat SCH. In order to determine the extent of CDCA metabolism to taurine or glycine conjugates (TCDCA or GCDC), respectively, during the 10-min incubation in the accumulation studies, WT rat SCH were treated using the above method for measuring accumulation of CDCA at 37°C, except that the dosing solution contained either vehicle (0.1% DMSO) or 1 μM unlabeled CDCA only. Following the final washes, wells were aspirated and plates were stored at −70°C until analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS) for TCDCA and GCDC, as well as for the rodent-specific BAs taurouricholic acid (TMCA) and glycomuricholic acid (GMCA), which are metabolites of CDCA. CDCA, TCDCA, and GCDC were measured using standard curves prepared with stable isotope equivalents; TMCA and GMCA were estimated from standard curves for TCA and glycocholic acid (GCA). Ten microliters of d4-TCDCA, d4-GCDCA, d8-TCA, and d4-GCA solutions in methanol were added to previously frozen untreated rat SCH plates to yield a final concentration of 0.5–100 pmol per well (0.5–200 pmol per well for TCA) as standards. Lysis solution (750 μl; 70:30 [vol/vol] methanol:water containing 19 pmol per well d8 TCA as an internal standard) was added to each well of study plates and to the plates containing standards. Plates were shaken on a rotating plate shaker at a speed of 500 rpm for 15 min. The total contact time of the lysis solution with cells, prior to filtration, was −20 to 30 min. The cell lysates were transferred to a Whatman 96-well UNIFilter Plate (Whatman, Florham Park, NJ) with 25 μm melt blown polypolypropylene over 0.45 μm polypolypropylene membrane. Lysate was filtered into a Greiner 96-well Deepwell Plate by centrifugation at 2000 × g for 5 min. Filterate was evaporated to dryness under nitrogen gas, reconstituted in 200 μl of sample diluent (60:40 [vol/vol] methanol:10mM ammonium acetate [native pH]), and mixed for 15 min on the plate shaker at 500 rpm. The reconstituted samples were transferred to a Whatman 96-well UNIFilter Plate with 0.45 μm PVDF (polyvinylidene fluoride) membrane and collected into a Costar 3956 96-well plate (Corning, Corning, NY) by centrifugation at 2000 × g for 5 min. The 96-well plate was sealed with a silicone capmat prior to LC-MS/MS analysis. Liquid handling during these procedures was accomplished using a Hamilton Microlab STAR liquid handling workstation and Tomtec Quadra 96 320 96-well simultaneous pipetting workstation.

**TABLE 1**

Transitions Monitored at Unit Resolution for LC-MS/MS Analysis of Parent CDCA and Taurine- and Glycine-Conjugated CDCA Metabolites in Cell Lysates from WT Rat SCH Following a 10-min Incubation with 1μM CDCA

<table>
<thead>
<tr>
<th>Analyte</th>
<th>Molecular weight</th>
<th>Salt</th>
<th>Retention time (min)</th>
<th>Precursor m/z</th>
<th>Product m/z</th>
<th>Calibration curve range</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCA</td>
<td>515.7</td>
<td>None</td>
<td>5.7</td>
<td>514</td>
<td>124</td>
<td>n/a</td>
</tr>
<tr>
<td>d4-TCA</td>
<td>519.7</td>
<td>None</td>
<td>5.7</td>
<td>514</td>
<td>124</td>
<td>Internal standard</td>
</tr>
<tr>
<td>d8-TCA</td>
<td>545.73</td>
<td>Na⁺</td>
<td>5.7</td>
<td>522</td>
<td>128</td>
<td>0.5–200 pmol per well</td>
</tr>
<tr>
<td>GCA</td>
<td>465.62</td>
<td>None</td>
<td>5.8</td>
<td>464</td>
<td>74</td>
<td>n/a</td>
</tr>
<tr>
<td>d4-GCA</td>
<td>469.65</td>
<td>None</td>
<td>5.8</td>
<td>468</td>
<td>74</td>
<td>0.5–100 pmol per well</td>
</tr>
<tr>
<td>TCDCA</td>
<td>499.7</td>
<td>None</td>
<td>8.1</td>
<td>498</td>
<td>80</td>
<td>n/a</td>
</tr>
<tr>
<td>d4-TCDCA</td>
<td>503.73</td>
<td>None</td>
<td>8.1</td>
<td>502</td>
<td>80</td>
<td>0.5–100 pmol per well</td>
</tr>
<tr>
<td>GCDC</td>
<td>449.62</td>
<td>None</td>
<td>8.1</td>
<td>448</td>
<td>74</td>
<td>n/a</td>
</tr>
<tr>
<td>d4-GCDC</td>
<td>453.65</td>
<td>None</td>
<td>8.1</td>
<td>452</td>
<td>74</td>
<td>0.5–100 pmol per well</td>
</tr>
<tr>
<td>CDCA</td>
<td>392.57</td>
<td>None</td>
<td>10.2</td>
<td>409</td>
<td>124</td>
<td>5–1000 pmol per well</td>
</tr>
</tbody>
</table>

EQEF OF TRO ON CDCA DISPOSITION 373

Initial uptake of [14C]CDCA and [3H]TCA in WT rat suspended hepatocytes. The initial uptake of substrate (0.5 μM unlabeled CDCA plus 0.5 μM [14C]CDCA, 25 nCi/ml, or 1 μM TCA plus trace [3H]TCA, 60 nCi/ml) in WT rat suspended hepatocytes was measured in the presence of vehicle, 10 μM TRO, or 50 μM MK571 using standard methods (Leslie et al., 2007) with modifications. Uptake was performed in Na+-containing buffer to measure total uptake (Na+-dependent and Na+-independent) and in Na+-free choline-containing buffer to measure Na+-independent uptake. Na+-dependent uptake was calculated as the difference in uptake between the two conditions. The viability of freshly isolated hepatocytes was >90% as measured by trypan blue exclusion. Briefly, cells were washed 2 times in ice-cold buffer containing sodium chloride or in buffer in which choline chloride was substituted for sodium chloride (137 mM NaCl or choline chloride, 0.8 mM MgSO4, 10 mM 4-(2-hydroxyethyl)-1-piperazinanesulfonic acid (HEPES) 1.2 mM CaSO4, 0.86 mM K2HPO4, 0.14 mM KH2PO4, and 5 mM glucose, pH 7.4). Cells were resuspended at 1.0 × 10⁶ cells/ml in the same buffer and kept on ice for immediate use. Aliquots of cells (4 ml) in bottom-inverted Erlenmeyer flasks were preincubated at 37°C in a shaking water bath for 5 min. Vehicle (0.3% DMSO), 10 μM TRO, or 50 μM MK571 was added 15 s prior to the addition of [14C]CDCA or [3H]TCA. At 15, 30, and 45 s, 200 μl of cells (4 ml) of the cell suspension were removed, placed in a 0.4 ml polyethylene tube over a top layer of silicone oil:mineral oil (82:18 [vol/vol], 100 μl) and a bottom layer of 3 M KOH (50 μl), and immediately centrifuged. Radioactivity in the cell pellet and in the supernatant was measured by liquid scintillation counting. Adherent fluid volume was determined by incubating cells with [14C]julin (60 nCi/ml) using the method of Eauw et al. (1975). Uptake was normalized to protein concentrations in the incubation mixtures as measured at the end of each experiment using the BCA assay (Pierce Biotechnology, Inc., Rockford, IL).

Data analysis. The biliary excretion index (BEI), which represents the percentage of accumulated substrate that is excreted into bile canaliculi,
RESULTS

Accumulation of [14C]CDCA Species in WT and TR− Rat SCH

Accumulation of [14C]CDCA species in cells + bile and cells was compared in WT and TR− rat SCH, respectively, following a 10-min coincubation with 1.2μM [14C]CDCA and vehicle control (CTL), increasing concentrations of TRO (1–100μM) or 50μM MK571. In WT rat SCH, 1 and 10μM TRO had no significant effect on accumulation of [14C]CDCA species in cells + bile or cells compared with CTL, but 100μM TRO significantly decreased cell + bile accumulation, increased cellular accumulation nearly twofold compared with CTL, and markedly inhibited the biliary excretion of [14C]CDCA species; the BEI was reduced from −60 to 3% (Fig. 1). MK571 completely inhibited the biliary excretion and significantly increased cellular accumulation of [14C]CDCA species 2.8-fold over CTL.

Accumulation of [14C]CDCA species and [3H]TCA also was measured in TR− rat SCH to determine whether loss of Mrp2 altered the biliary excretion of [14C]CDCA species. Accumulation of [14C]CDCA species in CTL TR− cells + bile and cells (Fig. 2) was similar to WT CTL values (Fig. 1). TRO (10 and 100μM) significantly decreased cells + bile accumulation of [14C]CDCA species. Cellular accumulation of [14C]CDCA species was notably increased over CTL in the presence of 100μMTRO and 50μM MK571, and BEI values decreased from −56 in CTL to −6% and −10%, respectively, consistent with inhibition of the biliary excretion of [14C]CDCA species. For comparison, TCA accumulation also was measured in TR− SCH (Fig. 3). [3H]TCA accumulation in CTL cells + bile was −8.5-fold lower than the accumulation of [14C]CDCA species in cells + bile of TR− rat SCH, similar to differences in [14C]CDCA accumulation (Fig. 1) and [3H]TCA accumulation published previously (Marion et al., 2007) in WT rat SCH. In contrast to [14C]CDCA species, both 10 and 100μM TRO, as well as 50μM MK571, significantly decreased cells + bile accumulation of [3H]TCA; although there was a trend toward decreased cellular accumulation of TCA in TR− rat SCH, the differences were not statistically significant.

The BEI of [14C]CDCA species was similar between control WT and TR− rat SCH, and TRO decreased the BEI of...
[14C]CDCA species in a concentration-dependent manner. Although MK571 ablated the biliary excretion of [14C]CDCA in WT cells, the effect in TR– rat SCH was not as pronounced. BEI values for [3H]TCA in TR– rat SCH also were decreased by TRO and MK571, but the decreases in BEI observed with 100 μM TRO and MK571 for [3H]TCA were less than the decreases in BEI for [14C]CDCA species at the same concentrations.

MK571-Mediated Inhibition of [3H]TCA Accumulation Is Concentration Dependent

MK571 significantly inhibited [3H]TCA accumulation in cells + bile in WT rat SCH in a concentration-dependent manner (Fig. 4), and there was a clear trend toward increased cellular accumulation of [3H]TCA with increasing MK571 concentration. The BEI of [3H]TCA also was decreased in a concentration-dependent manner; 50 μM MK571 completely ablated biliary excretion of [3H]TCA in WT rat SCH.

Accumulation of [14C]CDCA Species and [3H]TCA Is Temperature Dependent

The accumulation of [14C]CDCA species and [3H]TCA was measured at 4°C in WT rat SCH in order to rule out passive uptake. As expected, the uptake of [14C]CDCA species and [3H]TCA into cells + bile and cells was almost entirely ablated at 4°C, and biliary excretion was negligible, consistent with temperature-dependent active transport processes for both BAs (data not shown).

Unconjugated CDCA Is Metabolized in WT Rat SCH

In order to determine the extent of CDCA metabolism during the 10-min incubation period in the accumulation studies, BAs were measured by LC-MS/MS in rat SCH incubated with vehicle (0.1% DMSO; CTL) or 1 μM unlabeled CDCA; results are shown in Figure 5. Analysis revealed that endogenous unconjugated CDCA was below the limit of quantification in both cells + bile and cells in CTL SCH. In CTL cells, modest amounts of endogenous TCDA (6% of total) and small amounts of GCDCA and GMCA (1 and 3% of total, respectively) were measured, whereas TMCA was the most abundant BA measured (90% of total) (Table 2). TMCA was excreted extensively into bile (86% of total), whereas TCDA was excreted into bile to a lesser extent (11% of total); GCDCA and GMCA accounted for 1 and 2%, respectively, of the BAs in bile (Table 2).

Following a 10-min incubation of WT rat SCH with exogenously administered CDCA, unconjugated CDCA accumulated in cells; cellular TCDA increased ~15-fold, GCDCA increased ~14-fold, and GMCA increased approximately threefold compared with CTL values (Fig. 5). Biliary excretion of CDCA and GMCA in the bile of cells exposed to exogenous CDCA was negligible, whereas TCDA in bile increased approximately fourfold. Interestingly, although cells + bile accumulation of TMCA did not change between CTL and treated cells, cellular accumulation increased approximately twofold and accumulation in bile decreased 21%. Overall, following the 10-min incubation, the accumulation in cells + bile of exogenously administered unlabeled CDCA including its conjugates (the difference in total BAs before and after exogenous CDCA exposure) was about 322 pmol/mg protein, which is consistent with the accumulation of [14C]CDCA species in cells + bile in WT CTL SCH (~325 pmol/mg protein, Fig. 1). This indicates that the CDCA species detected by LC-MS/MS represent the majority, if not all, of the parent and metabolites. As summarized in Table 2, following
TABLE 2
Accumulation (% Total) of CDCA, TCDCA, GCDCA, TMCA, and GMCA in Cells and Bile of Rat SCH Following a 10-Min Incubation with Vehicle (0.1% DMSO; CTL) or with 1µM Exogenous CDCA (Treated)

<table>
<thead>
<tr>
<th></th>
<th>CTL Cells</th>
<th>CTL Bile</th>
<th>Treated Cells</th>
<th>Treated Bile</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDCA</td>
<td>0</td>
<td>0</td>
<td>22</td>
<td>4</td>
</tr>
<tr>
<td>TCDCA</td>
<td>6</td>
<td>11</td>
<td>21</td>
<td>34</td>
</tr>
<tr>
<td>GCDCA</td>
<td>1</td>
<td>1</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>TMCA</td>
<td>90</td>
<td>86</td>
<td>50</td>
<td>54</td>
</tr>
<tr>
<td>GMCA</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

exogenous exposure to CDCA, the amount of TCDCA, GCDCA, and unconjugated CDCA increased as a percentage of the total BAs measured in cells and bile, whereas the percentage of TMCA within the cells and bile decreased as a percentage of the total; only modest changes in GMCA were noted.

Initial Uptake of $[^{14}\text{C}]$CDCA Is Primarily Na$^+$-Independent, Whereas $[^{3}\text{H}]$TCA Uptake Is Primarily Na$^+$-Dependent

Initial uptake of $[^{14}\text{C}]$CDCA and $[^{3}\text{H}]$TCA was measured in WT rat suspended hepatocytes at 15, 30, and 45 s (Fig. 6). Pilot studies indicated that uptake of both BAs was linear through 90 s (data not shown). TRO and MK571 significantly inhibited total $[^{14}\text{C}]$CDCA uptake to a similar extent when compared with CTL (Fig. 6A). Na$^+$-independent uptake of $[^{14}\text{C}]$CDCA at 45 s in CTL cells (Fig. 6B) was $65 \pm 5\%$ of total uptake of $[^{14}\text{C}]$CDCA at 45 s in CTL cells in the presence of Na$^+$ (set at 100%; Fig. 6A) and was double the Na$^+$-independent uptake of $[^{3}\text{H}]$TCA at 45 s in CTL cells (Fig. 6E). Both TRO and MK571 significantly inhibited Na$^+$-independent $[^{14}\text{C}]$CDCA uptake (Fig. 6B); Na$^+$-dependent uptake (Fig. 6C) also was inhibited. For comparison, initial uptake of $[^{3}\text{H}]$TCA was measured under the same conditions as $[^{14}\text{C}]$CDCA. TRO and MK571 significantly inhibited total $[^{3}\text{H}]$TCA uptake to a similar extent at all time points (Fig. 6D). Na$^+$-independent uptake of $[^{3}\text{H}]$TCA at 45 s in CTL cells (Fig. 6E) was $34 \pm 12\%$ of total $[^{3}\text{H}]$TCA uptake at 45 s in CTL cells (set at 100%; Fig. 6D), consistent with previous reports demonstrating that TCA uptake in rat hepatocytes is mediated primarily by a Na$^+$-dependent process (Kemp et al., 2005; Van Dyke et al., 1982). Both TRO and MK571 significantly inhibited Na$^+$-independent $[^{3}\text{H}]$TCA uptake at 45 s (Fig. 6F) and also inhibited Na$^+$-dependent $[^{3}\text{H}]$TCA uptake (Fig. 6F).

DISCUSSION

Inhibition of BA transport, which may cause toxic intracellular accumulation of BAs, is one hypothesized mechanism of TRO toxicity. Although a number of in vivo and in vitro studies have reported that TRO inhibits transport of the prototypic BA TCA, the present study demonstrates that TRO differentially affects the disposition of BAs, specifically CDCA and TCA, in primary rat hepatocytes following acute exposure. The accumulation of $[^{14}\text{C}]$CDCA in cells + bile in WT rat SCH was approximately sixfold higher than accumulation of $[^{3}\text{H}]$TCA in cells + bile [historically ~40 to 70 pmol/mg protein (Lee et al., 2010; McRae et al., 2006; Wolf et al., 2010)]. This is consistent with previously published data indicating that the rate of uptake of CDCA in suspended rat hepatocytes was ~10-fold higher than that of TCA (Iga and Klaassen, 1982). In contrast to reports using $[^{3}\text{H}]$TCA as a model substrate (Ansede et al., 2010; Kemp et al., 2005; Marion et al., 2007), exposure to 1 or 10μM TRO did not significantly decrease accumulation of $[^{14}\text{C}]$CDCA species in cells + bile or in cells. In fact, treatment with 100μM TRO significantly increased intracellular accumulation and completely ablated the biliary excretion of $[^{14}\text{C}]$CDCA species. These results are significant because they are the first to demonstrate that TRO causes intracellular accumulation of a BA species in hepatocytes in vitro without uncoupling uptake from efflux, as discussed below.

MK571 also inhibited biliary excretion and caused significant cellular accumulation of $[^{14}\text{C}]$CDCA species. Hepatic MRP3/Mrp3 and MRP4/Mrp4 are upregulated under cholestatic conditions in both rat (Denk et al., 2004; Donner and Keppler, 2001) and human (Gradhand et al., 2008; Scheffer et al., 2002) liver, and are postulated compensatory routes for basolateral BA efflux. MK571 was expected to increase intracellular $[^{14}\text{C}]$CDCA accumulation by inhibiting basolateral efflux via Mrps; complete ablation of biliary excretion was not anticipated because Bsep is responsible for transporting both conjugated and unconjugated BAs into bile, and MK571 has not been reported to inhibit Bsep. In contrast to Bsep, which transports monovalent BAs, Mrp2 transports sulfate- and glucuronide-conjugated (divalent) BAs (Konig et al., 1999). Impaired biliary excretion of $[^{14}\text{C}]$CDCA by MK571 suggested that unconjugated $[^{14}\text{C}]$CDCA may be metabolized completely to an Mrp2 substrate (i.e., sulfate or glucuronide conjugate) during the 10-min incubation, or that MK571 inhibited Bsep-mediated biliary excretion of $[^{14}\text{C}]$CDCA species in rat SCH.

Mrp2-deficient TR$^{-}$ rat hepatocytes were utilized to elucidate a potential role for Mrp2 in the transport of $[^{14}\text{C}]$CDCA species, and to compare the effect of MK571 on transport of $[^{14}\text{C}]$CDCA species versus $[^{3}\text{H}]$TCA. Accumulation of $[^{14}\text{C}]$CDCA species in cells + bile and cells, and the BEI, were similar in vehicle-treated TR$^{-}$ compared with WT rat SCH, indicating that the lack of Mrp2 did not affect the disposition of $[^{14}\text{C}]$CDCA species in rat SCH. Furthermore, MK571 and TRO had similar effects on intracellular accumulation of $[^{14}\text{C}]$CDCA species in WT and TR$^{-}$ rat SCH. These data suggest that CDCA and/or CDCA metabolites...
are Bsep substrates and that MK571 inhibited Bsep-mediated biliary excretion.

In rats, ~95 to 98% of BAs are conjugated to taurine, and the remainder to glycine, whereas in humans, 75% of BAs are conjugated to glycine and 25% to taurine (Alvaro et al., 1986); conjugation increases aqueous solubility, facilitating biliary excretion (Kullak-Ublick et al., 2004). LC-MS/MS analysis revealed that when CDCA was administered exogenously to SCH, unconjugated CDCA, TCDCA, and GCDCA increased within the cells during the 10-min incubation. Of the total BAs in bile following exposure to CDCA, 88% of total biliary BAs were conjugated to taurine, 8% were conjugated to glycine, and 4% remained as unconjugated CDCA (Table 2). The present results are consistent with data from Hoffman et al. (1975), showing that when unconjugated CDCA was injected into rats, >90% was excreted into the bile as the taurine conjugate, <5% as unconjugated CDCA, and a small amount was excreted as the glycine conjugate (Hoffman et al., 1975). Both TRO and MK571 increased cellular accumulation of [14C]CDCA species in WT and TR− rat SCH; these results raise the possibility that in humans, TRO may cause intracellular accumulation of CDCA/CDCA species. GCDCA, in particular, is cytotoxic and has been shown to induce apoptosis in primary rat hepatocytes (Kaplowitz and DeLeve, 2003).

Several studies have shown that TRO inhibits uptake and biliary excretion of TCA in rat (Ansede et al., 2010; Kemp et al., 2005; Marion et al., 2007) and human (Marion et al., 2007) suspended hepatocytes and SCH, leading to unchanged or decreased intracellular accumulation. Consistent with these reports, in the present studies, 10 and 100µM TRO significantly decreased accumulation of [3H]TCA in cells + bile of TR− rat SCH, but had no significant effect on cellular
accumulation. In contrast, Jemnitz et al. (2010) used the method of Lengyel et al. (2008) to assess the effects of TRO on basolateral and canalicular efflux of TCA in SCH. In these studies, [3H]TCA was preloaded into rat and human SCH by incubating them with [3H]TCA in the absence of inhibitor; then, [3H]TCA was washed off, and cells were incubated with various inhibitors or vehicle in standard HBSS or in Ca2+- and Mg2+-free HBSS buffer. At the end of the 10-min incubation, effluxed [3H]TCA was measured in the buffer and in cells + bile or in cells. Using this method, 100μM TRO decreased bile efflux of [3H]TCA into the medium. These results established that TRO can cause the intracellular accumulation of TCA, which had not been shown using other methods in SCH. By preloading hepatocytes with TCA, any inhibitory effects of TRO on BA uptake were bypassed. However, this paradigm, which uncouples the uptake and efflux of BAs, does not realistically represent the in vivo situation. The intracellular accumulation of a substrate in hepatocytes is dependent upon both uptake and efflux processes. BAs are highly conserved through enterohepatic cycling; basolateral reuptake of BAs from the blood greatly exceeds BA synthesis, and intracellular BAs are excreted rapidly into the bile canaliculi. This vectorial transport of BAs from blood to bile represents the normal circulation of BAs. In previous studies using TCA to examine the disposition of BAs following TRO exposure, it appears that TRO-mediated inhibition of [3H]TCA uptake precluded any effects on intracellular [3H]TCA accumulation (Ansede et al., 2010; Kemp et al., 2005; Marion et al., 2007).

Suspended rat hepatocytes were utilized to examine the effects of TRO on the uptake of CDCA versus TCA. In previous studies, TRO inhibited TCA uptake in suspended rat (Kemp et al., 2005) and human (Marion et al., 2007) hepatocytes and in basolateral membrane vesicles (Snow and Moseley, 2006). Based on results in SCH, TRO and MK571 were expected to have little, if any, effect on initial uptake of CDCA in suspended rat hepatocytes. The uptake of CDCA reportedly occurs partially by a nonsaturable Na+-independent mechanism, hypothesized to be passive diffusion, and partially by a saturable process (Bartholomew and Billing, 1983; Iga and Klaassen, 1982; Van Dyke et al., 1982). In cultured rat hepatocytes, uptake of CDCA was significantly, but not completely, reduced by the removal of Na+ and also by ouabain, a Na+-K+-ATPase inhibitor (Van Dyke et al., 1982), suggesting a Na+-dependent component of uptake (i.e., Ntcp). Results of the present studies confirmed that the majority of [3H]TCA uptake was Na+-dependent, whereas [14C]CDCA uptake was primarily Na+-independent. Surprisingly, both TRO and MK571 decreased Na+-dependent and Na+-independent initial uptake of [14C]CDCA. MK571 reportedly inhibits OATP1B3 (Letchert et al. 2005) and OATP2B1 (Letchert et al., 2006), which would explain inhibition of the Na+-independent component of CDCA uptake. MK571 also inhibited Na+-dependent TCA uptake into hepatocytes. To our knowledge, there are no prior reports of MK571-mediated inhibition of NTCP/Ntcp.

Decreased initial uptake of [14C]CDCA in suspended rat hepatocytes is compatible with results in SCH. Given that total intracellular accumulation of BAs is dependent on uptake processes as well as canalicular and basolateral efflux processes, then total accumulation of [14C]CDCA species in cells in the presence of 10μM TRO may be the result of decreased uptake coupled with decreased efflux, resulting in no change in net accumulation relative to CTL. However, the increased intracellular [14C]CDCA accumulation with 100μM TRO may indicate that higher concentrations of TRO inhibit biliary excretion of [14C]CDCA to a greater extent than uptake. Thus, TRO may have different effects on uptake and efflux depending on the concentration at the site of transport.

In conclusion, TRO differentially affected the uptake and accumulation of CDCA species compared with TCA in rat SCH, causing an intracellular increase in CDCA species but not TCA. This supports the hypothesis that impaired BA transport is a potential mechanism of TRO hepatotoxicity. In addition to the known inhibitory effect of MK571 on MRPs, our results suggest that MK571 also inhibited Ntcp and Bsep. Overall, these results demonstrate that inhibitors of BA transport proteins may have differential effects on the disposition of individual BAs and suggest that use of a single BA substrate for transport studies (i.e., TCA) may yield an incomplete picture of a compound’s effects on overall BA disposition. Therefore, multiple BA species should be evaluated as more cytotoxic BAs may accumulate in hepatocytes, potentially contributing to toxicity.

FUNDING

National Institutes of Health, National Institute of General Medical Sciences (GM41935 to K.L.R.B); National Institutes of Health, National Institute of Environmental Health Sciences (T32-ES007126 to T.L.M).

REFERENCES


